Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We are encouraged by our strong pipeline and the next wave of innovation which we expect to fuel long term sustainable growth for Elanco |
| 2023 was a strong year |
| Against all of those metrics, we have inside the guide strong expectations to continue to make great progress |
| Our strong performance last year gives us confidence that are innovation, portfolio and productivity strategy is working and that our actions and investments to launch our new innovations and optimize our core portfolio are paying off |
| I think 2023, the second half really marks progress and momentum - two quarters at 5% constant currency growth, we doubled our innovation, we increased our debt pay down beyond our expectations, and as you look to ’24, the priorities remain the same - sustained growth on the top line, innovation and bringing innovation forward, and cash |
| farm animal to have a strong quarter, the 28% growth was significantly higher than we expected, which was the key contributor to us delivering above the top end of our revenue guidance |
| Fourth quarter growth was driven by innovation, strength across our farm animal business, improved conditions in the European pet health retail market, and increased price |
| Our fourth quarter sales growth drivers, along with the strength in our U.S |
| farm animal growth was driven by resupply for cattle vaccines, strong Experior growth, and favorable timing of poultry rotations |
| We delivered just over $4.4 billion in sales with 1% constant currency growth, driven by improved price, adoption of new products, and strength in international poultry |
| One we don’t talk as much about, but with this restructuring we’re really adding significant investment in AdTab in Europe that had a good strong finish to the year, so those would be the three key that I would point to |
| Both products benefited from the improved retail inventory situation in the U.S |
| We continue to prioritize free cash flow improvements, paying down debt and reducing leverage, and exceeded our debt pay down expectations from our November guidance |
| The durability and the diversity of our global farm animal business is well positioned for both revenue and market share growth in 2024 |
| We expect meaningful improvements in free cash flow conversion with $280 million to $320 million available for debt pay down, about four times more than our $76 million in 2023 |
| If you step back and look, we saw an eight-point improvement sequentially from down minus-9 in 2022 to minus-1 overall, and I see this from the standpoint of stronger portfolios, more share of voice, a stronger team |
| With respect to Ceresto and A-family, we’re not guiding by product today, but overall we are feeling good about the positioning of those in retail, and that’s a big place where we have leadership and we expect that leadership to continue |
| Then a lot of positive feedback, we had a tremendous interest and many, many applications and believe we selected a very experienced, strong sales force, and actually the transition has gone faster ad we don’t believe the distraction factor may be as high as we expected |
| We have a strong track record of delivering productivity and will continue to look for additional opportunities to more efficiently allocate capital |
| Overall, our pet health business is set up for improved performance and growth in 2024, even ahead of our anticipated new products in parasiticides and dermatology |
| Importantly, this management team is taking disciplined, decisive actions to improve our earnings potential and leverage profile over time, as evidenced by the sale of our aqua business for over a billion dollars of net proceeds, the restructuring announced today to reallocate resources to higher value creation areas, our investment in expanding our U.S |
| Our investments, our improved capabilities and experienced team delivered a return to top line growth in 2023, and that growth will continue in 2024 |
| Solid international farm animal growth of 3% was driven by continued strength in international poultry |
| International farm animal, the largest revenue contributor of our four quadrants delivered 4% constant currency revenue growth, primarily driven by increased price and strength in poultry, a result of robust underlying demand and share growth in key markets like the U.K., Brazil and China |
| farm animal business also delivered 4% growth for 2023, driven by increased price and strength in cattle and swine, with poultry improving in the fourth quarter |
| Despite this, we believe Elanco is uniquely well suited for growth this year |
| We are deeply grateful to our aqua team’s dedication to delivering to our customers, as well as our bigger purpose of enriching lives with animal protein |
| Importantly, with over a billion dollars of expected proceeds from this transaction combined with improved free cash flow from the business, we expect to accelerate debt pay down |
| It did land in line with our expectations in the quarter, but the bigger news is, yes, we’ve demonstrated the ability to scale our 2000 liter, which gives us confidence that we’ve got the capacity and the supply to really go into the marketplace full force, and we’re doing that with our new sales force right now |
| The core portfolio continues to stabilize, driven by stronger commercial capabilities, global omnichannel approach, and the complement of new innovation |
| Statement |
|---|
| The Advantage family sales declined 8% in the quarter, primarily driven by international markets |
| Finally in international pet health, the 1% constant currency revenue decline was primarily driven by demand pressure in the Spain retail market in the first half of the year, which more than offset the encouraging growth from the Credelio family and AdTab in Europe |
| Along with the gross margin headwinds from unfavorable mix and manufacturing performance, this was adversely impacted by approximately $18 million of unexpected items primarily relate to Argentina |
| vet clinic, a soft European economic environment in the first half of last year, and generic pressure and changes in regulatory requirements in the U.S |
| The decline was driven by an approximate 150 basis point headwind from slowing manufacturing output as we worked to reduce balance sheet inventory, as well as unfavorable manufacturing performance, including higher than expected inflation on certain key inputs and higher affiliate expenses, including a recently implemented higher import duty rate in Argentina, partially offset by improved price |
| Additionally, we expect a revenue headwind of approximately $50 million as a result of strategic choices to change our distribution model, primarily in Argentina, exit low margin distribution agreements, and the continued phase out of contract manufacturing agreements |
| Todd Young Chris, with respect to the manufacturing slowdown, embedded in our guidance for 2024 is a 150 to 170 basis point headwind from those plant slowdowns |
| Firstly with regard to the decline in pet health in 4Q and outlook, you spoke about competitive pressure in veterinary clinics |
| Continuing down the P&L, gross margin was 56.3%, a decrease of 30 basis points compared to last year |
| You’ll see Trifexis declined 21% in ’23, it’s down to being about $82 million in total revenues, so still a big product for us but one that we just know has greater competition there |
| business declined 5% as competitive pressure in the veterinary clinic was partially offset by innovation revenue, increased price, and an improved retail inventory situation compared to the reduced purchasing we experienced in the fourth quarter of last year |
| While we expect a limited amount of top line headwind from the shift to distribution markets, we do not expect our restructuring efforts to have a meaningful downside to sales otherwise, notably in international farm animal markets where we expect to realize savings |
| Continuing down the income statement on Slide 14, gross margin decreased 440 basis points to 50.1% |
| For pet health globally, we declined 1% in constant currency in the quarter |
| We do expect volumes down in 2024 |
| There is always the seasonality and weather factors, there’s some economics we’ve seen, more on the retail side where there’s some trade-down, and the competitive pressure inside the vet clinic |
| You’ll also see both Ceresto and Advantage family were down last year - again, a lot of that’s in the vet clinic |
| Volumes were down in 2023, but less than they were in 2022 |
| I think we know parasiticides is really an uninvolved category for pet parents and vets |
| While we exceeded our sales expectations and demonstrated strong operating expense management for the quarter, adjusted EBITDA was adversely impacted by approximately $18 million of unexpected items, primarily related to the 54% devaluation of the Argentinean peso that occurred in December |
Please consider a small donation if you think this website provides you with relevant information